Evaluation of Post Hospital Administration of Celecoxib Following Minimally Invasive Knee Replacement Surgery
Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the benefits of continuing celecoxib through six weeks of total knee
arthroplasty recovery. This is a randomized, double blind study with a group of approximately
130 primary total knee patients. All patients will receive celecoxib throughout their
hospitalization as per current minimally invasive total knee arthroplasty protocol. At the
time of hospital discharge, participating patients will be randomly placed on either
celecoxib 200mg twice a day or a placebo twice a day.
This study will determine if the continued use of celecoxib for six weeks after total knee
arthroplasty hospitalization will further decrease narcotic consumption, improve knee range
of motion, improve ambulatory ability, and improve patient satisfaction over patients
receiving celecoxib only during the acute hospitalization.